The σ2 receptor: A novel protein for the imaging and treatment of cancer

Journal of Medicinal Chemistry

Volumn 56, Issue 18, 2013, Pages 7137-7160

  Mach, Robert H ^a   Zeng, Chenbo ^a   Hawkins, William G ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; ALISERTIB; ANTINEOPLASTIC AGENT; BARASERTIB; CCT 137690; DOCETAXEL; DOXORUBICIN; ENMD 2076; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GSK 461364; HYDROXYUREA; LU 28 179; METHOTREXATE; MK 5108; ON 01910NA; PIPERAZINE DERIVATIVE; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR MEMBRANE COMPONENT 1; SIGMA 2 OPIATE RECEPTOR; SIRAMESINE; SNS 314; STAUROSPORINE; TOZASERTIB; UNCLASSIFIED DRUG; VOLASERTIB; VX 689; ZM 44739;

BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CELL DEATH; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; DRUG BINDING SITE; DRUG CONFORMATION; FLUORESCENCE MICROSCOPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIGAND BINDING; LIPOPHILICITY; MOLECULAR PROBE; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NONHUMAN; RECEPTOR BINDING; RECEPTOR DENSITY; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; CELL PROLIFERATION; DRUG DISCOVERY; HUMANS; MOLECULAR IMAGING; MOLECULAR PROBES; NEOPLASMS; RECEPTORS, SIGMA;

EID: 84884480040     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301545c     Document Type: Review

References (171)

1. Martin, W. R.; Eades, C. G.; Thompson, J. A.; Huppler, R. E.; Gilbert, P. E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog J. Pharmacol. Exp. Ther. 1976, 197, 517-532
2. Matsumoto, R. R. Sigma Receptors: Historical Perspective and Background. In Sigma Receptors: Chemistry, Cell Biology and Clinical Implications; Matsumoto, R. R.; Bowen, W. D.; Su, T.-P., Eds.; Springer Science: New York, NY, 2007; pp 1-23.
3. Collier, T. L.; Waterhouse, R. N.; Kassiou, M. Imaging sigma receptors: applications in drug development Curr. Pharm. Des. 2007, 13, 51-72 (Pubitemid 46085300)
4. 3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain Eur. J. Pharmacol. 1981, 75, 81-82
5. 3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain J. Pharmacol. Exp. Ther. 1982, 223, 284-290
6. Tam, S. W. Naloxone-inaccessible sigma receptor in rat central nervous system Proc. Natl. Acad. Sci. U.S.A. 1983, 80, 6703-6707 (Pubitemid 14240163)
7. 3H]haloperidol binding in guinea pig brain membranes Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 5618-5621 (Pubitemid 14000534)
8. Hellewell, S. B.; Bowen, W. D. A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain Brain Res. 1990, 527, 244-253 (Pubitemid 20289511)
9. Walker, J. M.; Bowen, W. D.; Walker, F. O.; Matsumoto, R. R.; De Costa, B.; Rice, K. C. Sigma receptors: biology and function Pharmacol. Rev. 1990, 42, 355-402
10. Hellewell, S. B.; Bruce, A.; Feinstein, G.; Orringer, J.; Williams, W.; Bowen, W. D. Rat liver and kidney contain high densities of sigma-1 and sigma-2 receptors: characterization by ligand binding and photoaffinity labeling Eur. J. Pharmacol. 1994, 268, 9-18
11. Maurice, T.; Junien, J. L.; Privat, A. Dehydroepiandrosterone sulfate attenuates dizocilpine-induced learning impairment in mice via sigma 1-receptors Behav. Brain Res. 1997, 83, 159-164 (Pubitemid 27086630)
12. 3H]SKF-10,047 binding to sigma-1 receptors in the mouse forebrain J. Neurosci. Res. 1996, 46, 734-743 (Pubitemid 26425477)
13. Romieu, P.; Martin-Fardon, R.; Bowen, W. D.; Maurice, T. Sigma-1 receptor-related neuroactive steroids modulate cocaine-induced reward J. Neurosci. 2003, 23, 3572-3576 (Pubitemid 36958464)
14. Fontanilla, D.; Johannessen, M.; Hajipour, A. R.; Cozzi, N. V.; Jackson, M. B.; Ruoho, A. E. The hallucinogen N, N -dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator Science 2009, 323, 934-937
15. 1-binding site Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 8072-8077 (Pubitemid 26277167)
16. Seth, P.; Leibach, F. H.; Ganapathy, V. Cloning and structural analysis of the cDNA and the gene encoding the murine type 1 sigma receptor Biochem. Biophys. Res. Commun. 1997, 241, 535-540 (Pubitemid 28020136)
17. 1 binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export J. Pharmacol. Exp. Ther. 2003, 306, 718-725 (Pubitemid 36886173)
18. Palmer, C. P.; Mahen, R.; Schnell, E.; Djamgoz, M. B.; Aydar, E. Sigma-1 receptors bind cholesterol and remodel lipid rafts in breast cancer cell lines Cancer Res. 2007, 67, 11166-11175 (Pubitemid 350248541)
19. Tsai, S. Y.; Hayashi, T.; Mori, T.; Su, T. P. Sigma-1 receptor chaperones and diseases Cent. Nerv. Syst. Agents Med. Chem. 2009, 9, 184-189
20. Alonso, G.; Phan, V.; Guillemain, I.; Saunier, M.; Legrand, A.; Anoal, M.; Maurice, T. Immunocytochemical localization of the sigma-1 receptor in the adult rat central nervous system Neuroscience 2000, 97, 155-170 (Pubitemid 30195885)
21. Xu, J.; Zeng, C.; Chu, W.; Pan, F.; Rothfuss, J. M.; Zhang, F.; Tu, Z.; Zhou, D.; Zeng, D.; Vangveravong, S.; Johnston, F.; Spitzer, D.; Chang, K. C.; Hotchkiss, R. S.; Hawkins, W. G.; Wheeler, K. T.; Mach, R. H. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site Nat. Commun. 2011, 2, 380
22. Zeng, C.; Vangveravong, S.; Xu, J.; Chang, K. C.; Hotchkiss, R. S.; Wheeler, K. T.; Shen, D.; Zhuang, Z. P.; Kung, H. F.; Mach, R. H. Subcellular localization of sigma-2 receptors in breast cancer cells using two-photon and confocal microscopy Cancer Res. 2007, 67, 6708-6716 (Pubitemid 47105517)
23. Zeng, C.; Vangveravong, S.; Jones, L. A.; Hyrc, K.; Chang, K. C.; Xu, J.; Rothfuss, J. M.; Goldberg, M. P.; Hotchkiss, R. S.; Mach, R. H. Characterization and evaluation of two novel fluorescent sigma-2 receptor ligands as proliferation probes Mol. Imaging 2011, 10, 1536-0121
24. Haller, J. L.; Panyutin, I.; Chaudhry, A.; Zeng, C.; Mach, R. H.; Frank, J. A. Sigma-2 receptor as potential indicator of stem cell differentiation Mol. Imaging Biol. 2012, 14, 325-335
25. Ablordeppey, S. Y.; Glennon, R. A. Pharmacophore Models for Sigma-1 Receptor Binding. In Sigma Receptors: Chemistry, Cell Biology and Clinical Implications; Matsumoto, R. R.; Bowen, W. D.; Su, T.-P., Eds.; Springer Science: New York, NY, 2007; pp 71-98.
26. Vilner, B. J.; John, C. S.; Bowen, W. D. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines Cancer Res. 1995, 55, 408-413
27. Hall, E. J.; Giaccia, A. J. Radiobiology for the Radiologist, 6 th ed.; Lippencott Williams and Wilkins Publishing: Philidelphia, PA, 2006; p 656.
28. Masunaga, S.; Ono, K. Significance of the response of quiescent cell populations within solid tumors in cancer therapy J. Radiat. Res. 2002, 43, 11-25 (Pubitemid 135693382)
29. Mach, R. H.; Wheeler, K. T. Imaging the proliferative status of tumors with PET J. Labelled Compd. Radiopharm. 2007, 50, 366-369 (Pubitemid 47309018)
30. Loddo, M.; Kingsbury, S. R.; Rashid, M.; Proctor, I.; Holt, C.; Young, J.; El-Sheikh, S.; Falzon, M.; Eward, K. L.; Prevost, T.; Sainsbury, R.; Stoeber, K.; Williams, G. H. Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer Br. J. Cancer 2009, 100, 959-970
31. Fornace, A. J.; Fuks, Z.; Weichselbaum, R. R.; Milas, L. Radiation Therapy. In The Molecular Basis of Cancer, 2 nd ed.; Mendelsohn, J.; Howley, P. M.; Israel, M. A.; Liotta, L. A., Eds.; W. B. Saunders Co.: Philadelphia, PA, 2001; pp 423-466.
32. Collins, I.; Garrett, M. D. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors Curr. Opin. Pharmacol. 2005, 5, 366-373 (Pubitemid 40932038)
33. Strebhardt, K.; Ullrich, A. Targeting polo-like kinase 1 for cancer therapy Nat. Rev. Cancer 2006, 6, 321-330
34. Wallen, C. A.; Higashikubo, R.; Dethlefsen, L. A. Murine mammary tumour cells in vitro. II. Recruitment of quiescent cells Cell Tissue Kinet. 1984, 17, 79-89 (Pubitemid 14199682)
35. Wallen, C. A.; Higashikubo, R.; Dethlefsen, L. A. Murine mammary tumour cells in vitro. I. The development of a quiescent state Cell Tissue Kinet. 1984, 17, 65-77 (Pubitemid 14199681)
36. Mach, R. H.; Smith, C. R.; al-Nabulsi, I.; Whirrett, B. R.; Childers, S. R.; Wheeler, K. T. Sigma-2 receptors as potential biomarkers of proliferation in breast cancer Cancer Res. 1997, 57, 156-161 (Pubitemid 27020346)
37. Al-Nabulsi, I.; Mach, R. H.; Wang, L. M.; Wallen, C. A.; Keng, P. C.; Sten, K.; Childers, S. R.; Wheeler, K. T. Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumour cells Br. J. Cancer 1999, 81, 925-933 (Pubitemid 29516134)
38. Bem, W. T.; Thomas, G. E.; Mamone, J. Y.; Homan, S. M.; Levy, B. K.; Johnson, F. E.; Coscia, C. J. Overexpression of sigma receptors in nonneural human tumors Cancer Res. 1991, 51, 6558-6562
39. Wheeler, K. T.; Wang, L. M.; Wallen, C. A.; Childers, S. R.; Cline, J. M.; Keng, P. C.; Mach, R. H. Sigma-2 receptors as a biomarker of proliferation in solid tumours Br. J. Cancer 2000, 82, 1223-1232 (Pubitemid 30128883)
40. Bowen, W. D.; Bertha, C. M.; Vilner, B. J.; Rice, K. C. CB-64D and CB-184: ligands with high sigma-2 receptor affinity and subtype selectivity Eur. J. Pharmacol. 1995, 278, 257-260
41. Bertha, C. M.; Mattson, M. V.; Flippen-Anderson, J. L.; Rothman, R. B.; Xu, H.; Cha, X. Y.; Becketts, K.; Rice, K. C. A marked change of receptor affinity of the 2-methyl-5-(3-hydroxyphenyl)morphans upon attachment of an (E)-8-benzylidene moiety: synthesis and evaluation of a new class of sigma receptor ligands J. Med. Chem. 1994, 37, 3163-3170 (Pubitemid 24317562)
42. Crawford, K. W.; Bowen, W. D. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines Cancer Res. 2002, 62, 313-322 (Pubitemid 34074021)
43. Crawford, K. W.; Coop, A.; Bowen, W. D. Sigma-2 receptors regulate changes in sphingolipid levels in breast tumor cells Eur. J. Pharmacol. 2002, 443, 207-209 (Pubitemid 34603617)
44. Bowen, W. D.; Vilner, B. J.; Williams, W.; Bertha, C. M.; Kuehne, M. E.; Jacobson, A. E. Ibogaine and its congeners are sigma-2 receptor-selective ligands with moderate affinity Eur. J. Pharmacol. 1995, 279, R1-3
45. Mach, R. H.; Smith, C. R.; Childers, S. R. Ibogaine possesses a selective affinity for sigma 2 receptors Life Sci. 1995, 57, PL57-PL62
46. 3 receptor ligand in NG-108 cells, selectively labels sigma-2 binding sites in guinea pig hippocampus J. Pharmacol. Exp. Ther. 1993, 267, 961-970
47. Ghelardini, C.; Galeotti, N.; Bartolini, A. Pharmacological identification of SM-21, the novel sigma-2 antagonist Pharmacol., Biochem. Behav. 2000, 67, 659-662 (Pubitemid 32103578)
48. Mach, R. H.; Wu, L.; West, T.; Whirrett, B. R.; Childers, S. R. The analgesic tropane analogue (+/-)-SM 21 has a high affinity for sigma-2 receptors Life Sci. 1999, 64, PL131-PL137
49. 3H]ANSTO-14 binding to the sigma-1 binding sites Nucl. Med. Biol. 1999, 26, 209-215 (Pubitemid 29125339)
50. Nguyen, V. H.; Kassiou, M.; Johnston, G. A.; Christie, M. J. Comparison of binding parameters of sigma-1 and sigma-2 binding sites in rat and guinea pig brain membranes: novel subtype-selective trishomocubanes Eur. J. Pharmacol. 1996, 311, 233-240 (Pubitemid 26330379)
51. Marrazzo, A.; Cobos, E. J.; Parenti, C.; Arico, G.; Marrazzo, G.; Ronsisvalle, S.; Pasquinucci, L.; Prezzavento, O.; Colabufo, N. A.; Contino, M.; Gonzalez, L. G.; Scoto, G. M.; Ronsisvalle, G. Novel potent and selective sigma ligands: evaluation of their agonist and antagonist properties J. Med. Chem. 2011, 54, 3669-3673
52. Mach, R. H.; Vangveravong, S.; Huang, Y.; Yang, B.; Blair, J. B.; Wu, L. Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs as sigma-2 receptor ligands Med. Chem. Res. 2002, 11, 380-398 (Pubitemid 36871903)
53. Vangveravong, S.; Xu, J.; Zeng, C.; Mach, R. H. Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl carbamate analogs as sigma2 receptor ligands Bioorg. Med. Chem. 2006, 14, 6988-6997 (Pubitemid 44307642)
54. Chu, W.; Xu, J.; Zhou, D.; Zhang, F.; Jones, L. A.; Wheeler, K. T.; Mach, R. H. New N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl phenylcarbamate analogs as sigma-2 receptor ligands: synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents Bioorg. Med. Chem. 2009, 17, 1222-1231
55. Mach, R. H.; Yang, B.; Wu, L.; Kuhner, R. J.; Whirrett, B. R.; West, T. Synthesis and sigma receptor binding affinities of 8-azabicyclo[3.2.1]octan- 3α-yl and 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamates Med. Chem. Res. 2001, 10, 339-355 (Pubitemid 32758414)
56. Kashiwagi, H.; McDunn, J. E.; Simon, P. O., Jr.; Goedegebuure, P. S.; Xu, J.; Jones, L.; Chang, K.; Johnston, F.; Trinkaus, K.; Hotchkiss, R. S.; Mach, R. H.; Hawkins, W. G. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy Mol. Cancer 2007, 6, 48
57. Hornick, J. R.; Xu, J.; Vangveravong, S.; Tu, Z.; Mitchem, J. B.; Spitzer, D.; Goedegebuure, P.; Mach, R. H.; Hawkins, W. G. The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine Mol. Cancer 2010, 9, 298
58. Kashiwagi, H.; McDunn, J. E.; Simon, P. O., Jr.; Goedegebuure, P. S.; Vangveravong, S.; Chang, K.; Hotchkiss, R. S.; Mach, R. H.; Hawkins, W. G. Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma J. Transl. Med. 2009, 7, 24
59. Perregaard, J.; Moltzen, E. K.; Meier, E.; Sanchez, C. Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-Aminoalkyl)-1 H -indoles J. Med. Chem. 1995, 38, 1998-2008
60. Moltzen, E. K.; Perregaard, J.; Meier, E. Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines J. Med. Chem. 1995, 38, 2009-2017
61. 2-ligand Lu 28-179 has potent anxiolytic-like effects in rodents J. Pharmacol. Exp. Ther. 1997, 283, 1323-1332 (Pubitemid 28016507)
62. Ostenfeld, M. S.; Fehrenbacher, N.; Hoyer-Hansen, M.; Thomsen, C.; Farkas, T.; Jaattela, M. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress Cancer Res. 2005, 65, 8975-8983 (Pubitemid 41377389)
63. 3 and sigma-2 receptor ligands Bioorg. Med. Chem. Lett. 2004, 14, 195-202 (Pubitemid 38010219)
64. 3 receptor ligands Bioorg. Med. Chem. 2005, 13, 77-87 (Pubitemid 39575694)
65. 18F]-3′Deoxy-3′-fluorothymidine positron emission tomography and breast cancer response to docetaxel Clin. Cancer Res. 2011, 17, 7664-7672
66. 2 receptor ligands as tools for the development of PET radiotracers Eur. J. Med. Chem. 2011, 46, 4733-4741
67. Xu, R.; Lever, J. R.; Lever, S. Z. Synthesis and in vitro evaluation of tetrahydroisoquinolinyl benzamides as ligands for sigma receptors Bioorg. Med. Chem. Lett. 2007, 17, 2594-2597 (Pubitemid 46507771)
68. Fan, K. H.; Lever, J. R.; Lever, S. Z. Effect of structural modification in the amine portion of substituted aminobutyl-benzamides as ligands for binding sigma-1 and sigma-2 receptors Bioorg. Med. Chem. 2011, 19, 1852-1859
69. Hajipour, A. R.; Guo, L. W.; Pal, A.; Mavlyutov, T.; Ruoho, A. E. Electron-donating para-methoxy converts a benzamide-isoquinoline derivative into a highly sigma-2 receptor selective ligand Bioorg. Med. Chem. 2011, 19, 7435-7440
70. Azzariti, A.; Colabufo, N. A.; Berardi, F.; Porcelli, L.; Niso, M.; Simone, G. M.; Perrone, R.; Paradiso, A. Cyclohexylpiperazine derivative PB28, a sigma-2 agonist and sigma-1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer Mol. Cancer Ther. 2006, 5, 1807-1816 (Pubitemid 44323249)
71. 2) receptor ligands: a review Cent. Nerv. Syst. Agents Med. Chem. 2009, 9, 205-219
72. Abate, C.; Niso, M.; Lacivita, E.; Mosier, P. D.; Toscano, A.; Perrone, R. Analogues of sigma receptor ligand 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4- tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with added polar functionality and reduced lipophilicity for potential use as positron emission tomography radiotracers J. Med. Chem. 2011, 54, 1022-1032
73. Colabufo, N. A.; Abate, C.; Contino, M.; Inglese, C.; Niso, M.; Berardi, F.; Perrone, R. PB183, a sigma receptor ligand, as a potential PET probe for the imaging of prostate adenocarcinoma Bioorg. Med. Chem. Lett. 2008, 18, 1990-1993 (Pubitemid 351380876)
74. Berardi, F.; Abate, C.; Ferorelli, S.; Uricchio, V.; Colabufo, N. A.; Niso, M.; Perrone, R. Exploring the importance of piperazine N-atoms for sigma-2 receptor affinity and activity in a series of analogs of 1-cyclohexyl-4-[3-(5- methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) J. Med. Chem. 2009, 52, 7817-7828
75. 3H)-one (SN79), a cocaine antagonist, in rodents AAPS J. 2011, 13, 336-346
76. Stavitskaya, L.; Seminerio, M. J.; Matthews-Tsourounis, M. M.; Matsumoto, R. R.; Coop, A. The effect of the pyridyl nitrogen position in pyridylpiperazine sigma ligands Bioorg. Med. Chem. Lett. 2010, 20, 2564-2565
77. 3H](+)pentazocine binding sites in the rat brain: autoradiographic visualization of the putative sigma-1 and sigma-2 receptor subtypes Neuroscience 1997, 76, 467-477 (Pubitemid 27008477)
78. 3H]1,3-di- o -tolylguanidine (DTG) binding sites in guinea pig brain: a comparative study Brain Res. 1992, 581, 33-38
79. Søby, K. K.; Mikkelsen, J. D.; Meier, E.; Thomsen, C. Lu 28-179 labels a sigma-2 site in rat and human brain Neuropharmacology 2002, 43, 95-100 (Pubitemid 35245678)
80. 3H] N -[4-(3,4-Dihydro-6,7-dimethoxyisoquinolin-2(1 H)-yl)butyl]-2-methoxy-5 -methylbenzamide: a novel sigma-2 receptor probe Eur. J. Pharmacol. 2005, 525, 8-17 (Pubitemid 41689015)
81. Colabufo, N. A.; Abate, C.; Contino, M.; Inglese, C.; Ferorelli, S.; Berardi, F.; Perrone, R. Tritium radiolabelling of PB28, a potent sigma-2 receptor ligand: pharmacokinetic and pharmacodynamic characterization Bioorg. Med. Chem. Lett. 2008, 18, 2183-2187 (Pubitemid 351380852)
82. 2 receptor ligand PB28 with the human nucleosome: computational and experimental probes of interaction with the H2A/H2B dimer ChemMedChem 2010, 5, 268-273
83. Hou, C.; Tu, Z.; Mach, R.; Kung, H. F.; Kung, M.-P. Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker Nucl. Med. Biol. 2006, 33, 203-209
84. 2-receptor ligand radiolabeled with fluorine-18 or iodine-125 as a PET/SPECT probe for imaging breast cancer Appl. Radiat. Isot. 2010, 68, 2268-2273
85. Tu, Z.; Xu, J.; Jones, L. A.; Li, S.; Dumstorff, C.; Vangveravong, S.; Chen, D. L.; Wheeler, K. T.; Welch, M. J.; Mach, R. H. Fluorine-18-labeled benzamide analogues for imaging the sigma-2 receptor status of solid tumors with positron emission tomography J. Med. Chem. 2007, 50, 3194-3204 (Pubitemid 47065968)
86. Tu, Z.; Dence, C. S.; Ponde, D. E.; Jones, L.; Wheeler, K. T.; Welch, M. J.; Mach, R. H. Carbon-11 labeled sigma-2 receptor ligands for imaging breast cancer Nucl. Med. Biol. 2005, 32, 423-430 (Pubitemid 40854092)
87. Kassiou, M.; Dannals, R. F.; Liu, X.; Wong, D. F.; Ravert, H. T.; Scheffel, U. A. Synthesis and in vivo evaluation of a new PET radioligand for studying sigma-2 receptors Bioorg. Med. Chem. 2005, 13, 3623-3626 (Pubitemid 40615914)
88. 18F-ISO-1 J. Nucl. Med. 2013, 54, 350-357
89. 2 receptor ligands for positron emission tomography (PET) J. Labelled Compd. Radiopharm. 2005, 48, 31-43
90. 76Br-labeled sigma-2 receptor ligands J. Nucl. Med. 2006, 47, 1041-1048 (Pubitemid 46939958)
91. 99mTc-labeled sigma-receptor-binding complex: synthesis, characterization, and specific binding to human ductal breast carcinoma (T47D) cells Bioconjugate Chem. 1997, 8, 304-309 (Pubitemid 27236494)
92. Mach, R. H.; Wheeler, K. T.; Blair, S.; Yang, B.; Day, C. S.; Blair, J. B.; Choi, S. R.; Kung, H. F. Preparation of a technetium-99m SPECT agent for imaging the sigma-2 receptor status of solid tumors J. Labelled Compd. Radiopharm. 2001, 44, 899-908 (Pubitemid 33081386)
93. Choi, S.-R.; Yang, B.; Plössl, K.; Chumpradit, S.; Wey, S.-P.; Acton, P. D.; Wheeler, K.; Mach, R. H.; Kung, H. F. Development of a Tc-99m labeled sigma-2 receptor-specific ligand as a potential breast tumor imaging agent Nucl. Med. Biol. 2001, 28, 657-666 (Pubitemid 32772868)
94. Vilner, B. J.; Bowen, W. D. Modulation of cellular calcium by sigma-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells J. Pharmacol. Exp. Ther. 2000, 292, 900-911 (Pubitemid 30136581)
95. Hertel, C.; Coulter, S. J.; Perkins, J. P. A comparison of catecholamine-induced internalization of beta-adrenergic receptors and receptor-mediated endocytosis of epidermal growth factor in human astrocytoma cells. Inhibition by phenylarsine oxide J. Biol. Chem. 1985, 260, 12547-12553 (Pubitemid 16233457)
96. Abate, C.; Hornick, J. R.; Spitzer, D.; Hawkins, W. G.; Niso, M.; Perrone, R.; Berardi, F. Fluorescent derivatives of sigma receptor ligand 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl] piperazine (PB28) as a tool for uptake and cellular localization studies in pancreatic tumor cells J. Med. Chem. 2011, 54, 5858-5867
97. Jiang, X.; Wang, X. Cytochrome c-mediated apoptosis Annu. Rev. Biochem. 2004, 73, 87-106 (Pubitemid 39050364)
98. Zeng, C.; Rothfuss, J.; Zhang, J.; Chu, W.; Vangveravong, S.; Tu, Z.; Pan, F.; Chang, K. C.; Hotchkiss, R.; Mach, R. H. Sigma-2 ligands induce tumour cell death by multiple signalling pathways Br. J. Cancer 2012, 106, 693-701
99. Berridge, M. J. The endoplasmic reticulum: a multifunctional signaling organelle Cell Calcium 2002, 32, 235-249 (Pubitemid 36175747)
100. Chwieralski, C. E.; Welte, T.; Buhling, F. Cathepsin-regulated apoptosis Apoptosis 2006, 11, 143-149 (Pubitemid 43291015)
101. Ostenfeld, M. S.; Hoyer-Hansen, M.; Bastholm, L.; Fehrenbacher, N.; Olsen, O. D.; Groth-Pedersen, L.; Puustinen, P.; Kirkegaard-Sorensen, T.; Nylandsted, J.; Farkas, T.; Jaattela, M. Anti-cancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation Autophagy 2008, 4, 487-499 (Pubitemid 351705145)
102. Gebreselassie, D.; Bowen, W. D. Sigma-2 receptors are specifically localized to lipid rafts in rat liver membranes Eur. J. Pharmacol. 2004, 493, 19-28 (Pubitemid 38746928)
103. Brown, D. A.; London, E. Functions of lipid rafts in biological membranes Annu. Rev. Cell Dev. Biol. 1998, 14, 111-136 (Pubitemid 29001451)
104. Simons, K.; Toomre, D. Lipid rafts and signal transduction Nat. Rev. Mol. Cell Biol. 2000, 1, 31-39
105. Patra, S. K. Dissecting lipid raft facilitated cell signaling pathways in cancer Biochim. Biophys. Acta 2008, 1785, 182-206
106. 2 receptor a histone binding protein? J. Med. Chem. 2006, 49, 4153-4158
107. Berardi, F.; Ferorelli, S.; Abate, C.; Colabufo, N. A.; Contino, M.; Perrone, R.; Tortorella, V. 4-(Tetralin-1-yl)- and 4-(naphthalen-1-yl)alkyl derivatives of 1-cyclohexylpiperazine as sigma receptor ligands with agonist sigma-2 activity J. Med. Chem. 2004, 47, 2308-2317 (Pubitemid 38478854)
108. Cahill, M. A. Progesterone receptor membrane component 1: an integrative review J. Steroid Biochem. Mol. Biol. 2007, 105, 16-36 (Pubitemid 47211947)
109. Peluso, J. J.; Liu, X.; Saunders, M. M.; Claffey, K. P.; Phoenix, K. Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1 J. Clin. Endocrinol. Metab. 2008, 93, 1592-1599 (Pubitemid 351656493)
110. Neubauer, H.; Clare, S. E.; Wozny, W.; Schwall, G. P.; Poznanovic, S.; Stegmann, W.; Vogel, U.; Sotlar, K.; Wallwiener, D.; Kurek, R.; Fehm, T.; Cahill, M. A. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1 Breast Cancer Res. 2008, 10, R85
111. Craven, R. J. PGRMC1: a new biomarker for the estrogen receptor in breast cancer Breast Cancer Res. 2008, 10, 113
112. Mir, S. U.; Ahmed, I. S.; Arnold, S.; Craven, R. J. Elevated progesterone receptor membrane component 1/sigma-2 receptor levels in lung tumors and plasma from lung cancer patients Int. J. Cancer 2012, 131, E1-E9
113. Ahmed, I. S.; Rohe, H. J.; Twist, K. E.; Mattingly, M. N.; Craven, R. J. Progesterone receptor membrane component 1 (PGRMC1): a heme-1 domain protein that promotes tumorigenesis and is inhibited by a small molecule J. Pharmacol. Exp. Ther. 2010, 333, 564-573
114. Ahmed, I. S.; Rohe, H. J.; Twist, K. E.; Craven, R. J. PGRMC1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity J. Biol. Chem. 2010, 285, 24775-24782
115. 2+ efflux from the endoplasmic reticulum and mitochondria in SK-N-SH cells Cell Calcium 2009, 45, 340-345
116. Meyer, C.; Schmid, R.; Scriba, P. C.; Wehling, M. Purification and partial sequencing of high-affinity progesterone-binding site(s) from porcine liver membranes Eur. J. Biochem. 1996, 239, 726-731 (Pubitemid 26253047)
117. Nolte, I.; Jeckel, D.; Wieland, F. T.; Sohn, K. Localization and topology of ratp28, a member of a novel family of putative steroid-binding proteins Biochim. Biophys. Acta 2000, 1543, 123-130
118. Min, L.; Strushkevich, N. V.; Harnastai, I. N.; Iwamoto, H.; Gilep, A. A.; Takemori, H.; Usanov, S. A.; Nonaka, Y.; Hori, H.; Vinson, G. P.; Okamoto, M. Molecular identification of adrenal inner zone antigen as a heme-binding protein FEBS J. 2005, 272, 5832-5843 (Pubitemid 41689355)
119. Raza, F. S.; Takemori, H.; Tojo, H.; Okamoto, M.; Vinson, G. P. Identification of the rat adrenal zona fasciculata/reticularis specific protein, inner zone antigen (IZAg), as the putative membrane progesterone receptor Eur. J. Biochem. 2001, 268, 2141-2147 (Pubitemid 32852956)
120. Peluso, J. J.; Pappalardo, A.; Losel, R.; Wehling, M. Progesterone membrane receptor component 1 expression in the immature rat ovary and its role in mediating progesterone's antiapoptotic action Endocrinology 2006, 147, 3133-3140 (Pubitemid 43764649)
121. Losel, R. M.; Besong, D.; Peluso, J. J.; Wehling, M. Progesterone receptor membrane component 1: many tasks for a versatile protein Steroids 2008, 73, 929-934
122. Su, T.-P.; London, E. D.; Jaffe, J. H. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems Science 1988, 240, 219-221
123. Johannessen, M.; Fontanilla, D.; Mavlyutov, T.; Ruoho, A. E.; Jackson, M. B. Antagonist action of progesterone at σ-receptors in the modulation of voltage-gated sodium channels Am. J. Physiol.: Cell Physiol. 2011, 300, C328-C337
124. Meyer, C.; Schmieding, K.; Falkenstein, E.; Wehling, M. Are high-affinity progesterone binding site(s) from porcine liver microsomes members of the sigma receptor family? Eur. J. Pharmacol. 1998, 347, 293-299 (Pubitemid 28234471)
125. Hughes, A. L.; Powell, D. W.; Bard, M.; Eckstein, J.; Barbuch, R.; Link, A. J.; Espenshade, P. J. Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes Cell Metab. 2007, 5, 143-149 (Pubitemid 46172917)
126. 3H] dextromethorphan and sigma ligands to guinea pig brain Life Sci. 1991, 48, 543-550
127. Ross, S. B. Heterogeneous binding of sigma radioligands in the rat brain and liver: possible relationship to subforms of cytochrome P-450 Pharmacol. Toxicol. 1991, 68, 293-301
128. Peluso, J. J. Non-genomic actions of progesterone in the normal and neoplastic mammalian ovary Semin. Reprod. Med. 2007, 25, 198-207 (Pubitemid 46676906)
129. Rohe, H. J.; Ahmed, I. S.; Twist, K. E.; Craven, R. J. PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding Pharmacol. Ther. 2009, 121, 14-19
130. Pgrmc1: the cytochrome-related sigma-2 receptor that regulates lipid and drug metabolism and hormone signaling Expert Opin. Drug Metab. Toxicol. 2012, 8, 361-370
131. Szczesna-Skorupa, E.; Kemper, B. Progesterone receptor membrane component 1 inhibits the activity of drug-metabolizing cytochromes P450 and binds to cytochrome P450 reductase Mol. Pharmacol. 2011, 79, 340-350
132. Peluso, J. J.; Liu, X.; Gawkowska, A.; Lodde, V.; Wu, C. A. Progesterone inhibits apoptosis in part by PGRMC1-regulated gene expression Mol. Cell. Endocrinol. 2010, 320, 153-161
133. 3H]3-PPP Eur. J. Pharmacol. 1986, 124, 183-187 (Pubitemid 16083598)
134. 125I]- N -(N -benzylpiperidin-4-yl)-4-iodobenzamide, a new sigma receptor radiopharmaceutical: high-affinity binding to MCF-7 breast tumor cells J. Med. Chem. 1994, 37, 1737-1739 (Pubitemid 24219763)
135. Vilner, B. J.; Bowen, W. D. Sigma receptor-active neuroleptics are cytotoxic to C6 glioma cells in culture Eur. J. Pharmacol. 1993, 244, 199-201 (Pubitemid 23028292)
136. Vilner, B. J.; de Costa, B. R.; Bowen, W. D. Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability J. Neurosci. 1995, 15, 117-134
137. John, C. S.; Vilner, B. J.; Geyer, B. C.; Moody, T.; Bowen, W. D. Targeting sigma receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors Cancer Res. 1999, 59, 4578-4583 (Pubitemid 29428962)
138. Megalizzi, V.; Le Mercier, M.; Decaestecker, C. Sigma receptors and their ligands in cancer biology: overview and new perspectives for cancer therapy Med. Res. Rev. 2012, 32, 410-427
139. Hornick, J. R.; Vangveravong, S.; Spitzer, D.; Abate, C.; Berardi, F.; Goedegebuure, P.; Mach, R. H.; Hawkins, W. G. Lysosomal membrane permeabilization is an early event in sigma-2 receptor ligand mediated cell death in pancreatic cancer J. Exp. Clin. Cancer Res. 2012, 31, 41
140. Zhang, Y.; Huang, Y.; Zhang, P.; Gao, X.; Gibbs, R. B.; Li, S. Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells Int. J. Nanomed. 2012, 7, 4473-4485
141. Peluso, J. J.; Gawkowska, A.; Liu, X.; Shioda, T.; Pru, J. K. Progesterone receptor membrane component-1 regulates the development and cisplatin sensitivity of human ovarian tumors in athymic nude mice Endocrinology 2009, 150, 4846-4854
142. Peluso, J. J. Progesterone signaling mediated through progesterone receptor membrane component-1 in ovarian cells with special emphasis on ovarian cancer Steroids 2011, 76, 903-909
143. Hornick, J. R.; Spitzer, D.; Goedegebuure, P.; Mach, R. H.; Hawkins, W. G. Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands Surgery 2012, 152, S152-156
144. Bowen, W. D. Sigma receptors: recent advances and new clinical potentials Pharm. Acta Helv. 2000, 74, 211-218 (Pubitemid 30182572)
145. van Waarde, A.; Rybczynska, A. A.; Ramakrishnan, N.; Ishiwata, K.; Elsinga, P. H.; Dierckx, R. A. Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands Curr. Pharm. Des. 2010, 16, 3519-3537
146. 123I-iodo-4-methoxybenzamide of patients with suspected primary breast cancer: first clinical results J. Nucl. Med. 2002, 43, 1647-1649 (Pubitemid 35424989)
147. Colabufo, N. A.; Berardi, F.; Contino, M.; Ferorelli, S.; Niso, M.; Perrone, R.; Pagliarulo, A.; Saponaro, P.; Pagliarulo, V. Correlation between sigma-2 receptor protein expression and histopathologic grade in human bladder cancer Cancer Lett. 2006, 237, 83-88
148. Bieberich, E. It's a lipid's world: bioactive lipid metabolism and signaling in neural stem cell differentiation Neurochem. Res. 2012, 37, 1208-1229
149. Spitzer, D.; Simon, P. O.; Kashiwagi, H.; Xu, J.; Zeng, C.; Vangveravong, S.; Zhou, D.; Chang, K.; McDunn, J. E.; Hornick, J. R.; Goedegebuure, P.; Hotchkiss, R. S.; Mach, R. H.; Hawkins, W. G. Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling Cancer Res. 2012, 72, 201-209
150. Kashiwagi, H.; McDunn, J. E.; Goedegebuure, P. S.; Gaffney, M. C.; Chang, K.; Trinkaus, K.; Piwnica-Worms, D.; Hotchkiss, R. S.; Hawkins, W. G. TAT-Bim induces extensive apoptosis in cancer cells Ann. Surg. Oncol. 2007, 14, 1763-1771 (Pubitemid 46790997)
151. Wang, Y.; Xu, J.; Xia, X.; Yang, M.; Vangveravong, S.; Chen, J.; Mach, R. H.; Xia, Y. SV119-gold nanocage conjugates: a new platform for targeting cancer cells via sigma-2 receptors Nanoscale 2012, 4, 421-424
152. Longley, D. B.; Harkin, D. P.; Johnston, P. G. 5-Fluorouracil: mechanisms of action and clinical strategies Nat. Rev. Cancer 2003, 3, 330-338 (Pubitemid 37328853)
153. Cohen, S. S.; Flaks, J. G.; Barner, H. D.; Loeb, M. R.; Lichtenstein, J. The mode of action of 5-fluorouracil and iits derivatives Proc. Natl. Acad. Sci. U.S.A. 1958, 44, 1004-1012
154. Whitfield, M. L.; George, L. K.; Grant, G. D.; Perou, C. M. Common markers of proliferation Nat. Rev. Cancer 2006, 6, 99-106 (Pubitemid 43361542)
155. Madaan, K.; Kaushik, D.; Verma, T. Hydroxyurea: a key player in cancer chemotherapy Expert Rev. Anticancer Ther. 2012, 12, 19-29
156. Vogel, W.; Schempp, W.; Sigwarth, I. Comparison of thymidine, fluorodeoxyuridine, hydroxyurea, and methotrexate blocking at the G1/S phase transition of the cell cycle, studied by replication patterns Hum. Genet. 1978, 45, 193-198 (Pubitemid 9041217)
157. Hande, K. R. Etoposide: four decades of development of a topoisomerase II inhibitor Eur. J. Cancer 1998, 34, 1514-1521 (Pubitemid 28446331)
158. Burden, D. A.; Osheroff, N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme Biochim. Biophys. Acta 1998, 1400, 139-154 (Pubitemid 28475100)
159. Noguchi, S. Predictive factors for response to docetaxel in human breast cancers Cancer Sci. 2006, 97, 813-820 (Pubitemid 44151259)
160. Lok, W.; Klein, R. Q.; Saif, M. W. Aurora kinase inhibitors as anti-cancer therapy Anti-Cancer Drugs 2010, 21, 339-350
161. VanderPorten, E. C.; Taverna, P.; Hogan, J. N.; Ballinger, M. D.; Flanagan, W. M.; Fucini, R. V. The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model Mol. Cancer Ther. 2009, 8, 930-939
162. Boss, D. S.; Beijnen, J. H.; Schellens, J. H. M. Clinical experience with aurora kinase inhibitors: a review Oncologist 2009, 14, 780-793
163. Katayama, H.; Sen, S. Aurora kinase inhibitors as anticancer molecules Biochim. Biophys. Acta, Gene Regul. Mech. 2010, 1799, 829-839
164. Kollareddy, M.; Zheleva, D.; Dzubak, P.; Brahmkshatriya, P. S.; Lepsik, M.; Hajduch, M. Aurora kinase inhibitors: progress towards the clinic Invest. New Drugs 2012, 30, 2411-2432
165. Hara, J. Development of treatment strategies for advanced neuroblastoma Int. J. Clin. Oncol. 2012, 17, 196-203
166. Schoffski, P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology Oncologist 2009, 14, 559-570
167. Rudolph, D.; Steegmaier, M.; Hoffmann, M.; Grauert, M.; Baum, A.; Quant, J.; Haslinger, C.; Garin-Chesa, P.; Adolf, G. R. BI 6727, a polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity Clin. Cancer Res. 2009, 15, 3094-3102
168. Christoph, D. C.; Schuler, M. Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies Expert Rev. Anticancer Ther. 2011, 11, 1117-1132
169. Colabufo, N. A.; Berardi, F.; Contino, M.; Fazio, F.; Matarrese, M.; Moresco, R. M.; Niso, M.; Perrone, R.; Tortorella, V. Distribution of sigma receptors in EMT-6 cells: preliminary biological evaluation of PB167 and potential for in-vivo PET J. Pharm. Pharmacol. 2005, 57, 1453-1459 (Pubitemid 350066988)
170. Thomas, G. E.; Szucs, M.; Mamone, J. Y.; Bem, W. T.; Rush, M. D.; Johnson, F. E.; Coscia, C. J. Sigma and opioid receptors in human brain tumors Life Sci. 1990, 46, 1279-1286 (Pubitemid 20171439)
171. Barg, J.; Thomas, G. E.; Bem, W. T.; Parnes, M. D.; Ho, A. M.; Belcheva, M. M.; McHale, R. J.; McLachlan, J. A.; Tolman, K. C.; Johnson, F. E.; Coscia, C. J. In vitro and in vivo expression of opioid and sigma receptors in rat C6 glioma and mouse N18TG2 neuroblastoma cells J. Neurochem. 1994, 63, 570-574